NASDAQ:ADIL - Adial Pharmaceuticals Stock Price, Forecast & News

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Adial Pharmaceuticals Inc (NASDAQ:ADIL) posted its quarterly earnings data on Thursday, November, 14th. The company reported ($0.17) earnings per share for the quarter. View Adial Pharmaceuticals' Earnings History.

Adial Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Adial Pharmaceuticals.

2 analysts have issued 12-month price targets for Adial Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Adial Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 135.8% from the stock's current price. View Analyst Price Targets for Adial Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adial Pharmaceuticals.

News articles about ADIL stock have been trending positive on Sunday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adial Pharmaceuticals earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Adial Pharmaceuticals.

Adial Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 137,600 shares, an increase of 58.0% from the December 15th total of 87,100 shares. Based on an average daily trading volume, of 82,300 shares, the short-interest ratio is currently 1.7 days. Currently, 2.0% of the shares of the stock are short sold. View Adial Pharmaceuticals' Current Options Chain.

Some companies that are related to Adial Pharmaceuticals include Enlivex Therapeutics (ENLV), Catalyst Biosciences (CBIO), Elite Pharmaceuticals (ELTP), ESSA Pharma (EPIX), Catabasis Pharmaceuticals (CATB), IMMUTEP LTD/S (IMMP), Aclaris Therapeutics (ACRS), Trevena (TRVN), Eyenovia (EYEN), CTI BioPharma (CTIC), Oncolytics Biotech (ONCY), Trillium Therapeutics (TRIL), Cumberland Pharmaceuticals (CPIX), Neos Therapeutics (NEOS) and VERONA PHARMA P/S (VRNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Tandem Diabetes Care (TNDM), Adobe (ADBE), Advanced Micro Devices (AMD), New Age Beverages (NBEV), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Altria Group (MO) and AcelRx Pharmaceuticals (ACRX).

(ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADIL stock can currently be purchased for approximately $2.12.

Adial Pharmaceuticals has a market capitalization of $21.88 million. Adial Pharmaceuticals employs 3 workers across the globe.View Additional Information About Adial Pharmaceuticals.

The official website for Adial Pharmaceuticals is http://www.adialpharma.com/.

Adial Pharmaceuticals' mailing address is 1001 RESEARCH PARK BLVD. SUITE 100, CHARLOTTESVILLE VA, 22911. The company can be reached via phone at 434-422-9800 or via email at [email protected]